Repertoire Immune Medicines

Repertoire Immune Medicines is a Flagship Pioneering-founded biotech leveraging its proprietary DECODE platform to map the immune synapse and discover the specific codes governing T cell-antigen interactions. This platform underpins a pipeline of programmable immune medicines aimed at treating cancer by eliminating tumors and autoimmune diseases by restoring immune tolerance. The company is clinical-stage, has established a significant collaboration with Eli Lilly, and is led by a seasoned team with deep expertise in immunology and drug development.

Proprietary DECODE platform designed to comprehensively map the immune synapse by linking T cell receptors (TCRs) to their cognate antigen targets, enabling the discovery of immune codes for developing programmable immune medicines.

Repertoire competes in the crowded space of next-generation immunotherapies, facing companies developing TCR-T cell therapies (Adaptive Biotechnologies, Immunocore), autoimmune cell therapies (Sonoma Biotherapeutics), and other platform companies mapping immune responses. Its key differentiator is the comprehensive pairing of TCRs with antigens to enable precise immune programming.